Limits...
A multi ‐ biomarker follow ‐ up study of patients with multiple sclerosis

View Article: PubMed Central - PubMed

ABSTRACT

Objectives: This study aimed to examine the levels of the macrophage marker sCD163 and other biomarkers at the time of diagnosis of patients with either clinically isolated syndrome (CIS) or relapsing‐remitting multiple sclerosis (RRMS), and assess relation to clinical indicators of prognosis, disease activity (DA), and changes in the levels of these biomarkers at follow‐up.

Materials and methods: The clinical status and MRI were reevaluated in 56 patients more than 1 year after diagnosis with a median follow‐up time of 2 years. Levels of biomarkers in serum and cerebrospinal fluid (CSF) samples were evaluated by enzyme‐linked immunosorbent assays.

Results: There was no significant difference in time to DA between patients with CIS and RRMS. A high sCD163 ratio (>0.07) was significantly (P = 0.04) associated with time to DA in the untreated patient group. In 21 patients reevaluated with serum and CSF samples, the sCD163 ratio levels decreased from 0.068 to 0.054 (P = 0.026) in the CIS/RRMS‐treated group. The CSF CXCL13, CXCL13 ratio, CSF neurofilament light polypeptide and osteopontin levels also decreased significantly in the CIS/RRMS‐treated group.

Conclusions: The levels of all biomarkers changed concurrently with MS treatment. The sCD163 ratio was identified as a potential novel marker for time to DA.

No MeSH data available.


Related in: MedlinePlus

The Kaplan–Meier DA estimates in patients with baseline CIS and RRMS (A) and in treated and untreated patients (B). The plot shows the proportion of patients without DA (no attack, no EDSS, or MRI progression) as a function of time to DA (Months). We performed the nonparametric log‐rank test for statistics. Abbreviations: CIS, clinically isolated syndrome; RRMS, relapsing‐remitting MS; DA, disease activity.
© Copyright Policy - creativeCommonsBy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC5036432&req=5

brb3509-fig-0002: The Kaplan–Meier DA estimates in patients with baseline CIS and RRMS (A) and in treated and untreated patients (B). The plot shows the proportion of patients without DA (no attack, no EDSS, or MRI progression) as a function of time to DA (Months). We performed the nonparametric log‐rank test for statistics. Abbreviations: CIS, clinically isolated syndrome; RRMS, relapsing‐remitting MS; DA, disease activity.

Mentions: The number of patients registered with increased clinical and MRI markers of DA was 47 (27 with new relapse, 24 with new MRI lesion, and/or 20 with progression on EDSS). Although patients with CIS showed less progression during the first 12 months compared to patients with RRMS (Fig. 2A), there was no significant difference in time to DA over the entire study period (P = 0.87). The mean follow‐up periods of the two patient groups were equal. As shown in Figure 2B, time to DA was significantly shorter in the treated group compared to the nontreated group (P < 0.01).


A multi ‐ biomarker follow ‐ up study of patients with multiple sclerosis
The Kaplan–Meier DA estimates in patients with baseline CIS and RRMS (A) and in treated and untreated patients (B). The plot shows the proportion of patients without DA (no attack, no EDSS, or MRI progression) as a function of time to DA (Months). We performed the nonparametric log‐rank test for statistics. Abbreviations: CIS, clinically isolated syndrome; RRMS, relapsing‐remitting MS; DA, disease activity.
© Copyright Policy - creativeCommonsBy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC5036432&req=5

brb3509-fig-0002: The Kaplan–Meier DA estimates in patients with baseline CIS and RRMS (A) and in treated and untreated patients (B). The plot shows the proportion of patients without DA (no attack, no EDSS, or MRI progression) as a function of time to DA (Months). We performed the nonparametric log‐rank test for statistics. Abbreviations: CIS, clinically isolated syndrome; RRMS, relapsing‐remitting MS; DA, disease activity.
Mentions: The number of patients registered with increased clinical and MRI markers of DA was 47 (27 with new relapse, 24 with new MRI lesion, and/or 20 with progression on EDSS). Although patients with CIS showed less progression during the first 12 months compared to patients with RRMS (Fig. 2A), there was no significant difference in time to DA over the entire study period (P = 0.87). The mean follow‐up periods of the two patient groups were equal. As shown in Figure 2B, time to DA was significantly shorter in the treated group compared to the nontreated group (P < 0.01).

View Article: PubMed Central - PubMed

ABSTRACT

Objectives: This study aimed to examine the levels of the macrophage marker sCD163 and other biomarkers at the time of diagnosis of patients with either clinically isolated syndrome (CIS) or relapsing&#8208;remitting multiple sclerosis (RRMS), and assess relation to clinical indicators of prognosis, disease activity (DA), and changes in the levels of these biomarkers at follow&#8208;up.

Materials and methods: The clinical status and MRI were reevaluated in 56 patients more than 1&nbsp;year after diagnosis with a median follow&#8208;up time of 2&nbsp;years. Levels of biomarkers in serum and cerebrospinal fluid (CSF) samples were evaluated by enzyme&#8208;linked immunosorbent assays.

Results: There was no significant difference in time to DA between patients with CIS and RRMS. A high sCD163 ratio (&gt;0.07) was significantly (P&nbsp;=&nbsp;0.04) associated with time to DA in the untreated patient group. In 21 patients reevaluated with serum and CSF samples, the sCD163 ratio levels decreased from 0.068 to 0.054 (P&nbsp;=&nbsp;0.026) in the CIS/RRMS&#8208;treated group. The CSF CXCL13, CXCL13 ratio, CSF neurofilament light polypeptide and osteopontin levels also decreased significantly in the CIS/RRMS&#8208;treated group.

Conclusions: The levels of all biomarkers changed concurrently with MS treatment. The sCD163 ratio was identified as a potential novel marker for time to DA.

No MeSH data available.


Related in: MedlinePlus